About Peptor
Peptor is a Healthcare company based in Rehovot (Israel) founded in 1993, and was acquired by DeveloGen in November 2003. It operates as a protein therapeutics for diabetes and immune diseases were developed. The company was acqui-hired. Its focus areas include Life Sciences, Diabetes and Drugs. Its competitors include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
As of 18 August 2004, Peptor merged itself with Develogen (which itself was acquired by Evotec in July 2010). At the time of the merger Peptor was engaged in the development of novel therapeutic vaccines for the treatment of human autoimmune diseases and cancers. Peptors therapeutic approach is based on two platforms: (1) a class of proteins, known as heat shock proteins, that are able to modulate the immune system to reduce andor eliminate its destructive effects against the bodys own cells, and (2) proprietary technology to design, synthesize and screen large numbers of compounds for the discovery of novel therapeutics, referred to as SCAPL technology. Peptors lead product, DiaPep277, was in phase II of human clinical trials for the treatment of autoimmune diabetes. Peptor had several other compounds undergoing pre-clinical studies and research for the treatment of other autoimmune diseases, such as myasthenia gravis and rheumatoid arthritis. Shareholders included Teva Pharmaceuticals, Johnson Johnson, Citibank, Clal Biotechnology Industries, Nomura, Walden Israel, and the British 3i group.
Investors in Peptor
Peptor has secured backing from 1 investor. Prominent investors backing the company include DeveloGen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Novel therapeutics are discovered for metabolic and endocrine disorders. | 1996 | develogen.com | Gottingen, Germany |
Investor details for Peptor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Peptor
2 dated milestones of Peptor across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Peptor is founded.
- Exit Acquired by DeveloGen.
Competitors of Peptor
Peptor has 9 listed competitors in our database, 8 of them funded. They include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| huamedicine.com | 2011 | Shanghai, China | $125M | – | Glucokinase activators for type-2 diabetes treatment are developed. |
Detailed competitors of Peptor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as Peptor (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Peptor
Peptor was founded in 1993.
Peptor is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
As of 18 August 2004, Peptor merged itself with Develogen (which itself was acquired by Evotec in July 2010). At the time of the merger Peptor was engaged in the development of novel therapeutic vaccines for the treatment of human autoimmune diseases and cancers. Peptors therapeutic approach is based on two platforms: (1) a class of proteins, known as heat shock proteins, that are able to modulate the immune system to reduce andor eliminate its destructive effects against the bodys own cells, and (2) proprietary technology to design, synthesize and screen large numbers of compounds for the discovery of novel therapeutics, referred to as SCAPL technology. Peptors lead product, DiaPep277, was in phase II of human clinical trials for the treatment of autoimmune diabetes. Peptor had several other compounds undergoing pre-clinical studies and research for the treatment of other autoimmune diseases, such as myasthenia gravis and rheumatoid arthritis. Shareholders included Teva Pharmaceuticals, Johnson Johnson, Citibank, Clal Biotechnology Industries, Nomura, Walden Israel, and the British 3i group.
Peptor's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Peptor has 1 investor. Key investors include DeveloGen.
Yes. Peptor was acquired by DeveloGen in November 2003.